MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease

    R. Hughes, O. Bandmann, L. Ferraiuolo, H. Mortiboys (Sheffield, United Kingdom)

    Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…
  • 2024 International Congress

    iPLA2β controls ER-mitochondria tethering and Ca2+ transfer in Parkinson’s disease

    ZH. Lin, Y. Liu, NJ. Xue, BR. Zhang, JL. Pu (Hangzhou, China)

    Objective: In this study, we aimed to investigate whether Parkinson's disease (PD) associated calcium-independent phospholipase A2β (iPLA2β) regulates the integrity and functions of endoplasmic reticulum…
  • 2024 International Congress

    Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability

    M. de Sciscio, R. Bryant, S. Haylock-Jacobs, A. Day, S. Costello, T. Kimber (Adelaide, Australia)

    Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…
  • 2024 International Congress

    The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson’s Disease

    T. Shiraishi, K. Bono, Y. Iguchi, H. Okano (Minato-ku, Japan)

    Objective: We investigated the relationship between alternative autophagy and VPS35 D620N mutant-related PD pathogenesis. Background: VPS35 is critically involved in the mechanisms of neurodegeneration observed…
  • 2024 International Congress

    Istradefylline therapy for dystonia in Parkinson’s disease

    NAO. Kanzato, KOH. Nakachi, SAT. Mochizuki, (Okinawa, Japan)

    Objective: To clarify the basal ganglia network links between PD and Dystonia in PD (Dys-PD) co-occur, and to get the conceptually novel pharmacotherapy. Background: Dys-PD is one…
  • 2024 International Congress

    ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain

    Z. Zamfirov, D. Mugan, G. Ahluwalia (Annapolis, USA)

    Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…
  • 2024 International Congress

    Interaction of GCase and ganglioside GM1 in the aggregation of α-Synuclein

    F. Fierli, G. Uras, S. Lucas-Del Pozo, S. Koletsi, V. Lentini, M. Toffoli, P. Caboni, A. Schapira (London, United Kingdom)

    Objective: The objective of this work is to investigate the relationship between ganglioside GM1 levels and α-synuclein aggregation in the context of GBA1 mutations. Background:…
  • 2024 International Congress

    Efficacy of Audiovisual Neuromodulation in the Treatment of Parkinson’s Disease

    O. Alenikova, L. Parkhach, E. Bоsiakova, G. Zobnina (Minsk, Belarus)

    Objective: To evaluate the AVS effectiveness in depression, anxiety, autonomic disorders and visual dysfunction in PD patients. Background: The severity of non-motor dopa-resistant symptoms in…
  • 2024 International Congress

    Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson’s Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up

    V. Leclercq, B. Delsaut, V. Donckels, S. Dethy (Sint-Pieters-Leeuw, Belgium)

    Objective: The aim of the study is to assess the evolution of motor symptoms (MS), non-motor symptoms (NMS) and neuropsychological functions (NF) in Parkinson's disease…
  • 2024 International Congress

    Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model

    V. Lentini, G. Uras, A. Manca, M. El Faqir, S. Lucas, A. Schapira, A. Pantaleo (Sassari, Italy)

    Objective: This investigation centers on the potential influence of microgravity on α-synuclein aggregation, a hallmark feature of Parkinson's disease (PD) characterized by the formation of…
  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley